PharmaLundensis is a research company. The company's main focus is on the treatment of serious lung diseases. Diseases that the company specializes in include chronic obstructive pulmonary disease (COPD), chronic bronchitis, and influenza-induced pulmonary failure. In addition to its main business, technical systems for handling drug emissions are developed. PharmaLundensis has its headquarters in Lund.
CEO
Chairperson of the Board
Board
| Name | Capital % | Votes % | Date |
|---|---|---|---|
| Staffan Skogvall | 43,78 | 43,78 | 2025-12-23 |
| Vict Th Engwalls Stiftelse | 4,37 | 4,37 | 2025-12-23 |
| Arne Arvidsson | 1,89 | 1,89 | 2025-12-23 |
| Arne Skogvall | 1,86 | 1,86 | 2025-12-23 |
| Tommy Johansson | 0,96 | 0,96 | 2025-12-23 |
| Fredrik Källström | 0,93 | 0,93 | 2025-12-23 |
| Nordnet Pensionsförsäkring | 0,91 | 0,91 | 2025-12-23 |
| Monica Billgert | 0,84 | 0,84 | 2025-12-23 |
| Staffan Engelbert Bodén | 0,83 | 0,83 | 2025-12-23 |
| Mostafa Samadimaleh | 0,78 | 0,78 | 2025-12-23 |
2026-05-21 Interim Report 2026-Q1
2026-08-20 Interim Report 2026-Q2
2026-11-19 Interim Report 2026-Q3
2027-02-18 Year End Report 2026